PuSH - Publication Server of Helmholtz Zentrum München: Predicting disease activity score in rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs using machine learning models.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Salehi, F.* ; Zarifi, S.H.* ; Bayat, S.* ; Habibpour, M.* ; Asemanrafat, A.* ; Kleyer, A.* ; Schett, G.* ; Fritsch‐Stork, R.* ; Eskofier, B.M.

Predicting disease activity score in rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs using machine learning models.

Technologies 13, 350 - 350 (2025)

Publ. Version/Full Text

DOI

	Open Access Gold

Abstract
Metrics
Extra information

Rheumatoid arthritis (RA) is a chronic autoimmune disease marked by joint inflammation and progressive disability. While biological disease-modifying antirheumatic drugs (bDMARDs) have significantly improved disease control, predicting individual treatment response remains clinically challenging. This study presents a machine learning approach to predict 12-month disease activity, measured by DAS28-CRP, in RA patients beginning bDMARD therapy. We trained and evaluated eight regression models, including Ridge, Lasso, Support Vector Regression, and XGBoost, using baseline clinical features from 154 RA patients treated at University Hospital Erlangen. A rigorous nested cross-validation strategy was applied for internal model selection and validation. Importantly, model generalizability was assessed using an independent external dataset from the Austrian BioReg registry, which includes a more diverse, real-world RA patient population from across multiple clinical sites. The Ridge regression model achieved the best internal performance (MAE: 0.633, R2: 0.542) and showed strong external validity when applied to unseen BioReg data (MAE: 0.678, R2: 0.491). These results indicate robust cross-cohort generalization. By predicting continuous DAS28-CRP scores instead of binary remission labels, our approach supports flexible, individualized treatment planning based on local or evolving clinical thresholds. This work demonstrates the feasibility and clinical value of externally validated, data-driven tools for precision treatment planning in RA.

Impact Factor

Scopus SNIP

Altmetric

3.600

1.757